siRNAgen Therapeutics Corporation is a next-generation RNAi drug discovery company with SAMiRNA™ (Self-Assembled-Micelle inhibitory RNA) platform which has 3 major advantages overcoming the hurdles of RNAi therapeutics:
- No innate immune stimulation.
- Delivery to various tissues which has inflammation or neoplasia
- One step solid-phase synthesis and simple formulation greatly reduces the cost of production/QC. With the advantages of SAMiRNA™, novel anti-fibrosis drug is firstly advancing to clinical stage for various fibrotic diseases which are the cause of 45% mortality in developed countries. siRNAgen Therapeutics Corporation is an RNAi therapeutics spin-off from Bioneer Corporation. Bioneer has developed various RNAi technologies from high-throughput synthesis/screening to novel in-vivo siRNA since 2001. By harnessing the established high-through discovery infrastructure and incessant innovations, the company accelerates the development of novel therapeutics for the serious diseases.